Cargando…

HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer

BACKGROUND: Human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV‐positive OPSCC patient. METHODS: A comprehensive multivariate analysis with clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Cioni, Bianca, Jordanova, Ekaterina S., Hooijberg, Erik, van der Linden, Rianne, de Menezes, Renee X., Tan, Katherine, Willems, Stefan, Elbers, Joris B. W., Broeks, Annegien, Bergman, Andries M., Zuur, Charlotte L., de Boer, Jan Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519285/
https://www.ncbi.nlm.nih.gov/pubmed/30549362
http://dx.doi.org/10.1002/hed.25442
_version_ 1783418614463856640
author Cioni, Bianca
Jordanova, Ekaterina S.
Hooijberg, Erik
van der Linden, Rianne
de Menezes, Renee X.
Tan, Katherine
Willems, Stefan
Elbers, Joris B. W.
Broeks, Annegien
Bergman, Andries M.
Zuur, Charlotte L.
de Boer, Jan Paul
author_facet Cioni, Bianca
Jordanova, Ekaterina S.
Hooijberg, Erik
van der Linden, Rianne
de Menezes, Renee X.
Tan, Katherine
Willems, Stefan
Elbers, Joris B. W.
Broeks, Annegien
Bergman, Andries M.
Zuur, Charlotte L.
de Boer, Jan Paul
author_sort Cioni, Bianca
collection PubMed
description BACKGROUND: Human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV‐positive OPSCC patient. METHODS: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD‐L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients. RESULTS: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor‐associated macrophages (TAMs). High HLA‐DP/DQ/DR expression and low number of TAMs were associated with longer disease‐specific survival and disease‐free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis. CONCLUSIONS: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy.
format Online
Article
Text
id pubmed-6519285
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-65192852019-05-23 HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer Cioni, Bianca Jordanova, Ekaterina S. Hooijberg, Erik van der Linden, Rianne de Menezes, Renee X. Tan, Katherine Willems, Stefan Elbers, Joris B. W. Broeks, Annegien Bergman, Andries M. Zuur, Charlotte L. de Boer, Jan Paul Head Neck Original Articles BACKGROUND: Human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV‐positive OPSCC patient. METHODS: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD‐L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients. RESULTS: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor‐associated macrophages (TAMs). High HLA‐DP/DQ/DR expression and low number of TAMs were associated with longer disease‐specific survival and disease‐free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis. CONCLUSIONS: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy. John Wiley & Sons, Inc. 2018-12-14 2019-02 /pmc/articles/PMC6519285/ /pubmed/30549362 http://dx.doi.org/10.1002/hed.25442 Text en © 2018 The Authors. Head & Neck published by Wiley Periodicals, Inc This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Cioni, Bianca
Jordanova, Ekaterina S.
Hooijberg, Erik
van der Linden, Rianne
de Menezes, Renee X.
Tan, Katherine
Willems, Stefan
Elbers, Joris B. W.
Broeks, Annegien
Bergman, Andries M.
Zuur, Charlotte L.
de Boer, Jan Paul
HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
title HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
title_full HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
title_fullStr HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
title_full_unstemmed HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
title_short HLA class II expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
title_sort hla class ii expression on tumor cells and low numbers of tumor‐associated macrophages predict clinical outcome in oropharyngeal cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519285/
https://www.ncbi.nlm.nih.gov/pubmed/30549362
http://dx.doi.org/10.1002/hed.25442
work_keys_str_mv AT cionibianca hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT jordanovaekaterinas hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT hooijbergerik hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT vanderlindenrianne hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT demenezesreneex hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT tankatherine hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT willemsstefan hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT elbersjorisbw hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT broeksannegien hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT bergmanandriesm hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT zuurcharlottel hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer
AT deboerjanpaul hlaclassiiexpressionontumorcellsandlownumbersoftumorassociatedmacrophagespredictclinicaloutcomeinoropharyngealcancer